This implies that the bulk of the work in developing general AI can be achieved by building systems that match the perceptual and motor abilities of animals and that the subsequent step to human-level intelligence would be considerably smaller. This is good news because progress on the first goal can rely on the favored subjects of neuroscience research - rats, mice, and non-human primates - for which extensive and rapidly expanding behavioral and neural datasets can guide the way. Thus, we believe that the NeuroAI path will lead to necessary advances if we figure out the core capabilities that all animals possess in embodied sensorimotor interaction with the world. NeuroAI Grand Challenge: The Embodied Turing Test In 1950, Alan Turing proposed the "imitation game" as a test of a machine's ability to exhibit intelligent behavior indistinguishable from that of a human

Please bear me and point out if I said something wrong and glad to hear your voice). In the past five years, a series of Transformer-based models has been created and relevant works have been done. Pre-trained large language models with few-shot prompting becomes the new paradigm for tackling a broad range of NLP-related tasks. This is amazing and really useful for NLP applications. But no significant improvement of model architecture (algorithm side) has been done; everything is still transformer-based.

Artificial intelligence is already changing medicine across many specialties, and in gastroenterology, new AI developments are coming online at breakneck speed. AI protocols and devices are being created and refined so they can identify abnormalities in a colonoscopy, diagnose disease, predict outcomes, and assist with treatment. With some already in use and others with potential to come into practice in the next one to five years, the opportunities are endless for how AI can contribute to better, more efficient patient care. Research has shown that after being "trained" through machine learning with thousands of photos and videos from actual colonoscopies, a computer-assisted diagnosis system can accurately spot and diagnose abnormalities during colonoscopy. When refined and adopted, this technology could increase a skilled endoscopists' speed and effectiveness.

The longevity and biotechnology industries are focusing on aging in a big way, and it's beginning to show. The fields of Artificial Intelligence (AI) and regenerative medicine are putting their money on combating aging and age-related diseases, and the benefits are likely to be immense. While biotechnology and AI are relatively new concepts, the announcements of funding and collaboration yesterday by and between three companies are bringing those concepts that much closer to the forefront of medicine. Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec, a leading global contract research outsourcing provider based in Shanghai, China, serving the pharmaceutical, biotech, and medical device industries. "It's a big step not only for Insilico Medicine but for AI and the pharmaceutical industries," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

The longevity and biotechnology industries are focusing on aging in a big way, and it's beginning to show. The fields of Artificial Intelligence (AI) and regenerative medicine are putting their money on combating aging and age-related diseases, and the benefits are likely to be immense. While biotechnology and AI are relatively new concepts, the announcements of funding and collaboration yesterday by and between three companies are bringing those concepts that much closer to the forefront of medicine. Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec, a leading global contract research outsourcing provider based in Shanghai, China, serving the pharmaceutical, biotech, and medical device industries. "It's a big step not only for Insilico Medicine but for AI and the pharmaceutical industries," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

Hybrid approach: Semantic AI is the combination of methods derived from symbolic AI and statistical AI. Virtuously playing the AI piano means that for a given use case various stakeholders, not only data scientists, but also process owners or subject matter experts, choose from available methods and tools, and collaboratively develop workflows that are most likely a good fit to tackle the underlying problem. For example, one can combine entity extraction based on machine learning with text mining methods based on semantic knowledge graphs and related reasoning capabilities to achieve the optimal results. Data Quality: Semantically enriched data serves as a basis for better data quality and provides more options for feature extraction. This results in higher precision of prediction & classification calculated by machine learning algorithms.

Hybrid approach: Semantic AI is the combination of methods derived from symbolic AI and statistical AI. Virtuously playing the AI piano means that for a given use case various stakeholders, not only data scientists, but also process owners or subject matter experts, choose from available methods and tools, and collaboratively develop workflows that are most likely a good fit to tackle the underlying problem. For example, one can combine entity extraction based on machine learning with text mining methods based on semantic knowledge graphs and related reasoning capabilities to achieve the optimal results. Data Quality: Semantically enriched data serves as a basis for better data quality and provides more options for feature extraction. This results in higher precision of prediction & classification calculated by machine learning algorithms.

IMAGE: This is the overview of Pharma AI drug discovery pipeline. Thursday, July 27, 2017, Baltimore, Md., Insilico Medicine ("Insilico"), a Baltimore-based leader in artificial intelligence ("AI") for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited ("Juvenescence AI"). Juvenescence AI will develop the first compounds generated by Insilico's deep-learned drug discovery engines, which train over structural, functional, and phenotypic data in order to predict the biological activity of compounds. Insilico's platforms incorporate new AI techniques such as Generative Adversarial Networks in order to generate novel compounds with desired pharmacokinetic and pharmacodynamic properties. As part of the agreement, Juvenescence Limited ("Juvenescence"), the parent company of Juvenescence AI, made a direct investment into Insilico to further advance Insilico's drug discovery platform and develop a set of companion multi-modal disease biomarkers.